# Clinical Trials Data KIT - Document 54

# Detection of Methylated Reprimo in Plasma for Asymptomatic Gastric Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01774266

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Male or Female\n\* Age 40-70 y.o.\n\nExclusion Criteria:\n\n\* Gastric Cancer\n\* Dyspepsia\n\* Bleeding disorders",  
 "healthyVolunteers": true,  
 "sex": "ALL",  
 "minimumAge": "40 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "3000 population base study from rural area in south of Chile. This is area has one of the highest incidence of gastric cancer in the world (35/100.000).",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
The information provided doesn't state whether having a KIT gene mutation would exclude a patient. The criteria only mention Gastric Cancer, Dyspepsia, and Bleeding disorders as exclusion criteria. Therefore, having a KIT mutation \*itself\* doesn't appear to disqualify a patient. However, it's crucial to understand that:  
  
\* \*\*KIT mutations can be associated with certain cancers, including Gastrointestinal Stromal Tumors (GIST), which can sometimes occur in the stomach.\*\* If the patient's KIT mutation is related to gastric cancer or a precancerous condition, they would likely be excluded.  
\* \*\*This information is insufficient to definitively determine eligibility.\*\* A qualified medical professional involved in the trial would need to evaluate the patient's specific situation and the nature of their KIT mutation to make a final determination.  
  
In short, the provided criteria don't explicitly exclude KIT mutations, but more information is needed to assess eligibility fully.